Dummer, Reinhard, Lebbé, Celeste, Atkinson, Victoria, Mandalà, Mario, Nathan, Paul, Arance, Ana, Richtig, Erika, Yamazaki, Naoya, Robert, Caroline, Schadendorf, Dirk, Tawbi, Hussein A., Ascierto, Paolo A., Ribas, Antoni, Flaherty, Keith, Pakhle, Neha, Campbell, Katie, Gusenleitner, Daniel, Masood, Aisha, Brase, Jan Christoph, Gasal, Eduard and Long, Georgina V. (2020) Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i. Nature medicine, 26 (9).

Abstract

While recent 5-year analyses of Phase III trials in metastatic melanoma have demonstrated that checkpoint inhibitors and targeted therapy lead to long-term survival, many patients experience progression and novel treatment strategies are needed. In parts 1 and 2 of COMBI-i (NCT02967692), spartalizumab + dabrafenib + trametinib demonstrated an objective response rate of 78% (95% CI, 61%-90%) and a complete response rate of 44%. Additionally, exploratory biomarker identified baseline biomarkers as well as on-treatment modulations that may predict patients likely to achieve long-term benefit.

Item Type:	Article
Date Deposited:	21 Oct 2020 00:45
Last Modified:	21 Oct 2020 00:45
URI:	https://oak.novartis.com/id/eprint/42164